Glu-Urea-Lys(Ahx)-Hbed-Cc (ILLUCCIX Configuration A Kit for the Preparation of Ga-68 Glu-urea-Lys(ahx)-hbed-CC 25 mcg solution for injection Glass Vial)
Glu-Urea-Lys(Ahx)-Hbed-Cc risk profile, scheduling, and guidance for claims professionals and care workers . Also known as ILLUCCIX Configuration A Kit for the Preparation of Ga-68 Glu-urea-Lys(ahx)-hbed-CC 25 mcg solution for injection Glass Vial.
Glu-Urea-Lys(Ahx)-Hbed-Cc (brand names: ILLUCCIX Configuration A Kit for the Preparation of Ga-68 Glu-urea-Lys(ahx)-hbed-CC 25 mcg solution for injection Glass Vial) is classified as Low risk (1 risk points) by AllMeds. It is a S4 medication under the TGA in Australia. Radiopharmaceutical agent for diagnostic imaging with minimal occupational impairment risk.
Key Takeaways
- TGA Schedule: S4 in Australia
- Risk level: Low (1 points)
Scheduling and Classification
| Jurisdiction | Classification | Status |
|---|---|---|
| Australia (TGA) | S4 | Not PBS listed |
Risk Profile
Radiopharmaceutical agent for diagnostic imaging with minimal occupational impairment risk.
Regulatory and Compliance Guidance
When Glu-Urea-Lys(Ahx)-Hbed-Cc appears on a claimant's medication list, claims professionals should assess whether the prescribing is appropriate for the compensable injury, whether the duration is within guidelines, and whether there are interactions with other medications on the claim.
Australia TGA / PBS / State Schemes
Classified as S4 under the Therapeutic Goods Administration (TGA).
WorkSafe Victoria Drugs of Dependence Guidelines require monitoring for all S8 opioids. WorkCover QLD Pain Intervention Guidelines recommend multimodal pain management with opioids as a last resort.
United Kingdom NICE / MHRA / FPM
NICE NG193 (Chronic Pain) recommends against initiating opioids for chronic primary pain. The Faculty of Pain Medicine (FPM) Opioids Aware resource recommends structured opioid prescribing with regular review, dose limits, and documented tapering plans.
For personal injury claims in the UK, opioid prescribing duration and dose should be reviewed against NICE and FPM guidelines. Costs may be recoverable as a disbursement in high-value PI claims.
United States FDA / CDC / State WC
The CDC Clinical Practice Guideline for Prescribing Opioids (2022) recommends non-opioid therapies as first-line treatment for pain. When opioids are prescribed, the lowest effective dose should be used for the shortest duration needed.
For workers compensation claims, many states require prior authorization for opioids beyond initial acute prescribing. State drug formularies (e.g. California MTUS, Texas, New York) may restrict or require step therapy before opioid approval.
New Zealand ACC / BPAC NZ / Medsafe
BPAC NZ recommends reassessing opioid therapy at regular intervals and limiting duration. The NZ Opioid Prescribing B-QuiCK Guide provides structured prescribing and tapering protocols.
ACC (Accident Compensation Corporation) covers treatment-related medications for accepted claims. Opioid prescribing beyond guidelines may require ACC clinical review and approval.
Need to assess this medication across your caseload?
Run a full risk assessment including Glu-Urea-Lys(Ahx)-Hbed-Cc interactions and compliance checks.
AllMeds gives you instant risk assessments, compliance checks, and automated letters for every medication on a claim.
No credit card required. No signup for your first 2 questions.
Medical Disclaimer: This content is for informational purposes for claims professionals and care workers. It is not medical advice. Always consult a qualified healthcare professional for clinical decisions. Drug information is sourced from TGA, FDA, MHRA, PBS, NICE, and CDC databases and may not reflect the latest updates. AllMeds does not replace clinical judgement.